Aranscia will provide software solutions to facilitate the delivery of results from InterVenn's flagship glycoproteomic liquid biopsy test.

The partnership marks Cardio Diagnostics' first expansion outside the US and is focused on integrating the test within Dr. Lal PathLabs' laboratory and clinical network.

Of the 30 companies in the index, 18 saw their share prices rise over the year, while 11 saw their stock prices decline and one remained flat.